Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On July 12, 2021, Nicholas Maestas, age 41, joined Tempest Therapeutics, Inc.
(the "Company") as vice president, strategy and finance and is the Company's
principal financial officer. Prior to joining the Company, Mr. Maestas was head
of FP&A and strategic finance at Alector, Inc. since 2019. Prior to Alector, he
worked at Immune Design Corp. from 2014 to 2019, most recently as senior
director, corporate development & operations. Prior to joining Immune Design,
Mr. Maestas worked at Thermo Fisher Scientific, Becton Dickinson and Novartis
Vaccines and Diagnostics (formerly known as Chiron Corporation). Mr. Maestas
received his Bachelor of Arts from the University of California, Berkeley and
his Masters in Business Administration from The Wharton School, University of
Pennsylvania.
In connection with his employment, Mr. Maestas is entering into an employment
agreement and an indemnification agreement with the Company. Pursuant to his
employment agreement, Mr. Maestas will receive an annual base salary of $325,000
and will be eligible to receive an annual performance bonus with a target amount
equal to 30% of his base salary. In the event that Mr. Maestas experiences a
termination of his employment without "cause" or he resigns for "good reason"
outside of the "change in control period" (as such terms are defined in
Mr. Maestas's employment agreement), provided that he executes and makes
effective a release of claims against the Company and its affiliates,
Mr. Maestas will become entitled to (i) an amount equal to three months' annual
base salary, payable in a lump sum, (ii) an amount equal to any annual bonus for
any completed calendar year, to the extent earned but not yet paid at the time
of such termination, and (iii) premium payments for continued healthcare
coverage for a period of three months. In the event that Mr. Maestas experiences
a termination of his employment without cause or he resigns for good reason
during the change in control period, provided that he executes and makes
effective a release of claims against the Company and its affiliates,
Mr. Maestas will become entitled to (i) an amount equal to six months' base
salary and 50% of his target annual performance bonus, payable in a lump sum,
(ii) an amount equal to any annual bonus for any completed calendar year, to the
extent earned but not yet paid at the time of such termination; (iii) premium
payments for continued healthcare coverage for a period of six months; and
(iv) accelerated vesting of each outstanding unvested equity award, provided
that any performance-based vesting criteria will be treated in accordance with
the applicable award agreement or other applicable equity incentive plan
governing the terms of such equity award.
Additionally, Mr. Maestas was granted an option to purchase 23,225 shares of the
Company's common stock at an exercise price equal to the closing price of the
Company's common stock on July 12, 2021. Twenty-five percent of the shares
subject to the option will vest on July 12, 2022 and the remaining shares will
vest in equal monthly installments over the following 48 months. Mr. Maestas
will be eligible for annual equity awards under the Company's 2017 Equity
Incentive Plan.
Mr. Maestas has no family relationships with any director or executive officer
of the Company. There are no arrangements or understandings between Mr. Maestas
and any other persons pursuant to which he was selected as an officer of the
Company, and there are no transactions in which Mr. Maestas has an interest
requiring disclosure under Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses